Leading business intelligence provider GBI Research has released its latest research report, entitled “Generic Growth Strategies – “Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs”. The report provides a comprehensive overview of the generic drugs market in the US, the top five countries in the European Union (EU, covering the UK, France, Germany, Spain and Italy) and Japan. The report focuses on the detailed analysis of major strategies implemented by the top 10 generic companies in the generic drugs market along with company portfolios and strategic analysis. The report gives detail on the current landscape and changes that have structured the generic drugs market. The report also contains an impact analysis of the regulatory landscape in the major geographies pertaining to the generic drugs market. The report also provides in-depth analysis of the unmet needs, drivers and barriers that affect the global generics market.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
The global generics market generated revenues of approximately $162 billion with a growth of 9.3% in 2011, representing about 19% of generic market share in the international pharmaceutical market. The generic pharmaceutical industry is significantly fragmented; the top 10 pharmaceutical companies accounted for 26% of global generics sales by value in 2011. The US has very high levels of generic utilization, with nearly 80% of prescriptions dispensed being generics.
The pharmaceutical industry will experience major patent expiries during 2013–2020, of which 2014 to 2017 are expected to be peak years, with the loss of patents for drugs whose sales were worth more than $76 billion during 2011. By 2015, branded products with sales of up to $135 billion will go off-patent, giving generic pharmaceutical companies immense opportunities to capitalize on the market. Along with generic drugs, pharmaceutical companies will also have the opportunity to develop biosimilars, as biologics with 2011 sales of approximately $64 billion will go off-patent over the next five years.
Detailed study of generic growth strategies with special emphasis on strategies which help in combating intensive competition.
Analysis of the major strategies adopted by companies looking to expand geographical reach.
Analysis of the generic pharmaceutical market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan.
Key drivers and barriers that have a significant impact on the market.
Competitive benchmarking of leading companies. Key companies studied in this report are Teva, Sandoz, Mylan, Watson, Actavis, Hospira, Sanofi, Daiichi Sankyo, Aspen and STADA.
Reasons To Buy
Build understanding of the key generic growth strategies in place and the trends in the market.
Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the potential region and therapeutics market segments poised for strong growth.
Create a more tailored country strategy through the understanding of key drivers and barriers in the global generics market.
Optimize your R&D pipeline through the identification and understanding of the key strategy for your drug.
Identify the key players best positioned to capitalize on their products through the effective management of their patented products.
Develop effective business strategies related to generic drugs through the analytical insight gained from case studies covering different strategies in the market.